Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium

To report a case of impending recurrent pterygium treated with topical bevacizumab eyedrops.

A 53-year-old woman with impending recurrent pterygium was treated with topical bevacizumab eyedrops (25 mg/mL) administered 4 times daily for 3 weeks. Two months previously, she had undergone excision of a primary ptergyium in the same eye by bare sclera recision and application of mitomycin C.

Treatment with topical bevacizumab for 3 weeks produced prominent regression of limbal-conjunctival neovascularization. At 6-month follow-up, no recurrent pterygium was noted. Symptoms were resolved with no ocular irritation, burning, or any systemic adverse effects.

These data suggest that off-label short-term use of topical bevacizumab may be effective to prevent recurrence in a patient with impending recurrent pterygium. We believe that this is the first known successful use of topical bevacizumab in such a patient.